The company have substantially improved this course of the new treatment for ATTR-CM, employing the compound. Early clinical information indicates potential improvements for individuals suffering from a severe condition. This focus represents the company’s dedication to treating unmet healthcare demands in a heart field. Attruby: BridgeBio's Nov